心肌无复流防治的最新研究进展(3)
[5] Zhao JLZ，Fan CM，Yang YJ，et al.Chronic pretreatment of metforminis associatied with the reduction of the No-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction [J].Cardiovascular Therapeutics，2013，31(1)：60-64
[6] Jolly SS，Cairns JA，Yusuf S，et al.Outcomes after thrombus aspiration for ST elevation myocardial infarction：1-year follow-up of the prospective randomized TOTAL trial[J].Lancet，2016，387(10014)；127-135，DOI：10.1016/SO140-6736(15)00448-1.
, http://www.100md.com
[7] Windecker S，Kolh P，Alfonso F.et al.2014 ESC，EACTS Guidelines on myocardial revascularization：The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio—Thoracic Surgery(EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J，2014，35(37)：2541-2619.DOI：10.1093/eurheart/ehu278.
[8] 沈衛峰，张奇，张瑞岩.2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J].国际心血管杂志，2015，42(4)：217-219
, 百拇医药
[9] Elgendy IY， Huo T， Bhatt DL， et al. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention？ Meta-analysis of randomized trials. Circ Cardiovasc Interv. 2015；8：e002258.
[10] Piscione F，Danzi GB，Cassese S，et al.Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction：safety，feasibility and impact on myocardial infarction.Catheter Cardiovasc Interv.2010；75(5)：715-721.
, 百拇医药
[11] Dudek D，Dziewierz A，Rzeszutko L，et al.Mesh covered stent in ST-segment elevation myocardial infarction.Eurointervention.2010；6(5)：682-589.
[12] Fernandez-Cisnal A，Cid-Alvarez B，Alvarez-Alvarez B，et al.Real world comparison of the MGuard stent versus the bare metal stent for ST elevation myocardial infarction(the REWARD-MI study).Catheter Cardiovasc Interv.2015；85(1)：E1-E9.
[13] Costa RA， Abizaid A， Lotan C， et al. Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial). Am J Cardiol. 2015；115(2)：161–166.
, 百拇医药
[14] Gracida M， Ramaguera R， Jacobi F， Gomez-Hospital JA， Cequier A. The MGuard coronary stent： safety， efficacy and clinical utility. Vasc Health Risk Manag. 2015；11：533–539.
[15] Kloner RA， Forman MB， Gibbons RJ， Ross AM， Alexander RW， Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction： the AMISTAD-2 trial. Eur Heart J 2006；27：2400–5., http://www.100md.com(高杰张传焕)
[6] Jolly SS，Cairns JA，Yusuf S，et al.Outcomes after thrombus aspiration for ST elevation myocardial infarction：1-year follow-up of the prospective randomized TOTAL trial[J].Lancet，2016，387(10014)；127-135，DOI：10.1016/SO140-6736(15)00448-1.
, http://www.100md.com
[7] Windecker S，Kolh P，Alfonso F.et al.2014 ESC，EACTS Guidelines on myocardial revascularization：The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio—Thoracic Surgery(EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J，2014，35(37)：2541-2619.DOI：10.1093/eurheart/ehu278.
[8] 沈衛峰，张奇，张瑞岩.2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J].国际心血管杂志，2015，42(4)：217-219
, 百拇医药
[9] Elgendy IY， Huo T， Bhatt DL， et al. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention？ Meta-analysis of randomized trials. Circ Cardiovasc Interv. 2015；8：e002258.
[10] Piscione F，Danzi GB，Cassese S，et al.Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction：safety，feasibility and impact on myocardial infarction.Catheter Cardiovasc Interv.2010；75(5)：715-721.
, 百拇医药
[11] Dudek D，Dziewierz A，Rzeszutko L，et al.Mesh covered stent in ST-segment elevation myocardial infarction.Eurointervention.2010；6(5)：682-589.
[12] Fernandez-Cisnal A，Cid-Alvarez B，Alvarez-Alvarez B，et al.Real world comparison of the MGuard stent versus the bare metal stent for ST elevation myocardial infarction(the REWARD-MI study).Catheter Cardiovasc Interv.2015；85(1)：E1-E9.
[13] Costa RA， Abizaid A， Lotan C， et al. Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial). Am J Cardiol. 2015；115(2)：161–166.
, 百拇医药
[14] Gracida M， Ramaguera R， Jacobi F， Gomez-Hospital JA， Cequier A. The MGuard coronary stent： safety， efficacy and clinical utility. Vasc Health Risk Manag. 2015；11：533–539.
[15] Kloner RA， Forman MB， Gibbons RJ， Ross AM， Alexander RW， Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction： the AMISTAD-2 trial. Eur Heart J 2006；27：2400–5., http://www.100md.com(高杰张传焕)